Kymera Therapeutics, Inc. (NASDAQ:KYMR) CFO Bruce N. Jacobs Sells 7,035 Shares

Kymera Therapeutics, Inc. (NASDAQ:KYMR) CFO Bruce N. Jacobs sold 7,035 shares of the company’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total transaction of $214,215.75. Following the completion of the transaction, the chief financial officer now owns 201,886 shares of the company’s stock, valued at approximately $6,147,428.70. The trade was a 3.37 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Kymera Therapeutics Trading Down 3.8 %

Shares of Kymera Therapeutics stock traded down $1.18 during trading hours on Monday, hitting $30.17. 982,064 shares of the company were exchanged, compared to its average volume of 578,939. The business has a 50-day moving average of $38.81 and a 200-day moving average of $43.66. Kymera Therapeutics, Inc. has a 1 year low of $29.16 and a 1 year high of $53.27. The stock has a market capitalization of $1.95 billion, a price-to-earnings ratio of -12.89 and a beta of 2.18.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.12). The firm had revenue of $7.39 million for the quarter, compared to analysts’ expectations of $14.81 million. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. As a group, research analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on KYMR shares. Morgan Stanley boosted their price target on shares of Kymera Therapeutics from $45.00 to $49.00 and gave the company an “equal weight” rating in a research report on Wednesday, November 6th. Leerink Partners reissued an “outperform” rating and issued a $60.00 target price on shares of Kymera Therapeutics in a report on Friday, December 27th. HC Wainwright raised their price target on Kymera Therapeutics from $54.00 to $60.00 and gave the stock a “buy” rating in a research note on Friday. Wells Fargo & Company upgraded Kymera Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $38.00 to $57.00 in a research note on Monday, December 2nd. Finally, UBS Group lowered their target price on shares of Kymera Therapeutics from $80.00 to $74.00 and set a “buy” rating on the stock in a research report on Monday, November 4th. Three investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $56.69.

Institutional Investors Weigh In On Kymera Therapeutics

A number of hedge funds have recently added to or reduced their stakes in KYMR. Massachusetts Financial Services Co. MA raised its stake in shares of Kymera Therapeutics by 11.7% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 453,377 shares of the company’s stock worth $21,458,000 after buying an additional 47,507 shares in the last quarter. Eventide Asset Management LLC grew its holdings in Kymera Therapeutics by 9.9% during the third quarter. Eventide Asset Management LLC now owns 507,902 shares of the company’s stock worth $24,039,000 after acquiring an additional 45,803 shares during the period. Intech Investment Management LLC purchased a new position in Kymera Therapeutics in the third quarter worth $650,000. JPMorgan Chase & Co. lifted its holdings in Kymera Therapeutics by 212.6% in the third quarter. JPMorgan Chase & Co. now owns 140,491 shares of the company’s stock valued at $6,649,000 after acquiring an additional 95,547 shares during the period. Finally, Natixis Advisors LLC purchased a new stake in shares of Kymera Therapeutics during the 3rd quarter worth $681,000.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.